Please login to the form below

Not currently logged in

FDA approves two new IBS medicines

FDA headquarters White Oak

US regulator gives the nod to Actavis’ and Salix’ bowel drugs

Express Scripts pushes for pay-for-performance in cancer

UK Life Sciences Strategy - one year onStates it is the only way to fund the growing cost of cancer care

Sanofi licenses cardiovascular therapy in South Korea

Sanofi receptionPhase III drug comes from Swedish company NeuroVive

Boehringer bags FDA approval for Spiriva-based combo

Boehringer Ingelheim headquartersStiolto given the thumbs up as a once-daily maintenance therapy for COPD

Amgen’s immuno-oncology drug scores in skin cancer

Amgen flagFirm hoping its novel treatment will be on the market be the end of this year

Three cancer immunotherapies amongst new CHMP approvals

EU flagBMS’ Evotaz also amongst eight new medicine recommendations

Clinical research in children lagging, says report

Report found children are missing out on treatment advances that are helping adults

Amgen decision on brodalumab unsettles anti-IL-17 class

Amgen flagMove made following data found linking the drug to suicidal thoughts

AZ escapes censure over cancer tweet

AstraZeneca AZ headquarters London UKFirm did not breach UK’s Code of Practice over survival statistics post

Get Real! The Rise of Observational Data In Healthcare

Real world data is now becoming a serious research tool for pharma, but just what can it add to the golden standard that is the randomised clinical trial?

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Lucid Group Limited

Lucid are specialists committed to delivering excellent medical education that changes clinical practice. Our confidence in understanding therapy areas, together...

Latest intelligence

When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....
Forecasting for Licensed Compounds
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharmaceutical forecasting...